Small molecule-chemotherapy combinations: ibrutinib plus rituximab for CLL
Antibody-chemotherapy combinations are a standard treatment for hematological malignancies, and with an increase in small molecules coming through the pharmaceutical pipeline, the question is now will...
Author: VJHemOnc
Added: 01/17/2018 (Source: Oncology Tube)
Source: Oncology Tube - January 17, 2018 Category: Cancer & Oncology Source Type: podcasts
Small molecule-chemotherapy combinations: ibrutinib plus rituximab for CLL
Antibody-chemotherapy combinations are a standard treatment for hematological malignancies, and with an increase in small molecules coming through the pharmaceutical pipeline, the question is now will...
Author: VJOncology
Added: 01/16/2018 (Source: Oncology Tube)
Source: Oncology Tube - January 16, 2018 Category: Cancer & Oncology Source Type: podcasts
Rituximab After Bendamustine - Rituximab Maintenance Improved PFS
John M. Burke, MD from Rocky Mountain Cancer Centers discusses Rituximab after Bendamustine - Rituximab maintenance improved PFS at the 2017 American Society of Hematology.
Author: ASHReport
Added: 01/12/2018 (Source: Oncology Tube)
Source: Oncology Tube - January 12, 2018 Category: Cancer & Oncology Source Type: podcasts
Ibrutinib combination regimens for CLL from ASH 2017
Despite the combination of ibrutinib and rituximab not significantly affecting progression-free survival in patients with chronic lymphocytic leukemia (CLL), many groups are testing ibrutinib combinat...
Author: VJHemOnc
Added: 01/08/2018 (Source: Oncology Tube)
Source: Oncology Tube - January 8, 2018 Category: Cancer & Oncology Source Type: podcasts
An audit of infusion-related reactions with biosimilar rituximab in London
An important question regarding the use of biosimilar rituximab is whether rapid infusion rates are safe, as they are for the original. Speaking from the British Oncology Pharmacy Association (BOPA) 2...
Author: VJHemOnc
Added: 01/03/2018 (Source: Oncology Tube)
Source: Oncology Tube - January 3, 2018 Category: Cancer & Oncology Source Type: podcasts
The introduction of biosimilar rituximab: a case study from the pharmacist's perspective
"During the British Oncology Pharmacy Association (BOPA) 20th Annual Symposium for cancer care pharmacy in Glasgow, UK, Simon Cheesman, BPharm, MRPharmS from the University College London Hospita...
Author: VJHemOnc
Added: 12/13/2017 (Source: Oncology Tube)
Source: Oncology Tube - December 13, 2017 Category: Cancer & Oncology Source Type: podcasts
Two CLL Couples Connect: Our Shared Experiences
Patient Power Founder Andrew Schorr was treated at MD Anderson Cancer Center more than 17 years ago with FCR (fludarabine, cyclophosphamide, rituximab)<br />to combat his CLL. In 2017, Andrews physician ...
Author: patientpower
Added: 08/04/2017 (Source: Oncology Tube)
Source: Oncology Tube - August 4, 2017 Category: Cancer & Oncology Source Type: podcasts
Obinutuzumab vs. rituximab with chemotherapy in follicular lymphoma
Lauren C. Pinter-Brown MD, FACP, Health Sciences Professor of Medicine and Dermatology, Chao Family Comprehensive Cancer Center, UC-Irvine compares Obinutuzumab vs. rituximab with chemotherapy in fol...
Author: moasc
Added: 02/22/2017 (Source: Oncology Tube)
Source: Oncology Tube - February 23, 2017 Category: Cancer & Oncology Source Type: podcasts
Ibrutinib Combination Therapy Extremely Well Tolerated in Early Trial
Jennifer Brown, MD of Dana Farber, discusses a current and promising trial that combines ibrutinib with a standard chemo-immunotherapy combination: fludarabine, cyclophosphamide, rituximab (FCR), at t...
Author: ASHReport
Added: 12/09/2016 (Source: Oncology Tube)
Source: Oncology Tube - December 9, 2016 Category: Cancer & Oncology Source Type: podcasts
New CLL treatments, the standard of care and the importance of clonal evolution
Michael Hallek, MD, PhD of the University of Cologne, Cologne, Germany discusses new chronic lymphocytic leukemia (CLL) treatments and FCR (fludarabine, cyclophosphamide, and rituximab) at the 2016 In...
Author: VJHemOnc
Added: 11/03/2016 (Source: Oncology Tube)
Source: Oncology Tube - November 3, 2016 Category: Cancer & Oncology Source Type: podcasts
Trial results of idelalisib with bendamustine and rituximab in CLL
Andrew Zelenetz, MD, PhD, from Memorial Sloan-Kettering Cancer Center, New York, NY discusses the results of a Phase III trial of bendamustine and rituximab plus placebo vs bendamustine and rituximab ...
Author: VJHemOnc
Added: 07/05/2016 (Source: Oncology Tube)
Source: Oncology Tube - July 5, 2016 Category: Cancer & Oncology Source Type: podcasts
Discussion of a Phase III trial evaluating the efficacy and safety of idelalisib
Jacqueline Barrientos, MD from Northwell Health, New York, NY discuss a placebo-controlled study of idelalisib in combination with bendamustine plus rituximab, also known as BR (NCT01569295). The resu...
Author: VJHemOnc
Added: 07/05/2016 (Source: Oncology Tube)
Source: Oncology Tube - July 5, 2016 Category: Cancer & Oncology Source Type: podcasts
Idelalisib plus bendamustine and rituximab improves the outcome of relapsed/refractory CLL
Andrew Zelenetz, MD, PhD from the Memorial Sloan-Kettering Cancer Center, New York, NY gives a brief overview of relapsed/refractory chronic lymphocytic leukemia (CLL) and describes the results of a P...
Author: PatientPowerEU
Added: 03/21/2016 (Source: Oncology Tube)
Source: Oncology Tube - March 21, 2016 Category: Cancer & Oncology Source Type: podcasts
Progress in treatment options for precursor B-cell ALL
Elias Jabbour, MD from University of Texas MD Anderson Cancer Center, Houston, USA discusses a study for precursor B-cell ALL presented at ASH 2015 where a combination of chemotherapy with rituximab s...
Author: PatientPowerEU
Added: 03/04/2016 (Source: Oncology Tube)
Source: Oncology Tube - March 4, 2016 Category: Cancer & Oncology Source Type: podcasts
